Ventavis To Cost $65,000 - $100,000 Per Year, CoTherix Says

The PAH therapy is competitively priced against United Therapeutics' Remodulin and Actelion's Tracleer, CoTherix says. With its sales force still in training, Ventavis has launched ahead of schedule.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet